In the ECHELON-3 study, the brentuximab vedotin combination with lenalidomide and rituximab reduced mortality risk by 37% compared with placebo.

I will honor his request—giving back to the place that gave us more time, more hope, and more love than we could have ever asked for." The post Her late father asked her to run the Boston Marathon.

KIMSHEALTH Cancer Centre successfully treats high-grade B-cell lymphoma patient with CAR T-cell therapy, offering new hope.

Caribou Biosciences (CRBU) reported better-than-expected earnings in the first quarter, with top and bottom-line beats.

The following is a summary of “Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With ...

Enhanced assay granted approval by New York State’s Clinical Lab Evaluation Program (CLEP) for patients with DLBCL clonoSEQ is the only DLBCL MRD ...

Combination Targeted Treatment Produces Lasting Remissions in People With Resistant Aggressive B-Cell Lymphoma June 19, 2024 — Researchers have developed a non-chemotherapy treatment regimen ...

Matthew Matasar, MD, discussed what the findings from the ELM-1 trial of odronextamab in diffuse large B-cell lymphoma mean ...

Geoffrey Shouse, DO, PhD, discusses the growing interest in bispecific antibodies within the field of oncology.